Shanghai Argo Announced Multi-Program RNAi Licenses And Strategic Collaborations With Novartis

+2.29%

Novartis AG Sponsored ADR

NVS

0.00

Shanghai Argo Biopharmaceutical Co., Ltd. ("Argo"), a biotechnology company focused on the discovery and development of next-generation RNAi therapeutics, today announced that it has entered into two exclusive license and collaboration agreements with Novartis PHARMA AG ("Novartis").

- Argo will receive upfront payments of $185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.

- Novartis will receive an ex-Greater China exclusive license for a Phase 1/2a stage cardiovascular asset, a worldwide exclusive license for a Phase 1 stage cardiovascular asset as well as an option to license compounds directed against up to two cardiovascular targets.

- Discovered and developed with Argo's advanced RNA interference (RNAi) technology, these programs will reinforce and expand the Novartis RNAi portfolio on Cardiovascular and Metabolic diseases (CVM).

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Burlington (BURL) Analysts See Stronger Results Ahead but Does Momentum Signal Lasting Growth?

Will Cadre Holdings (CDRE) Benefit From Steady Defense Demand Amid Global Instability?

Could Eagle Materials' (EXP) Dividend and Buybacks Reveal a Strategic Shift in Capital Allocation?

Assessing Monster Beverage After Strong 37.7% Rally and Alcoholic Expansion News

Crown Holdings (CCK): Evaluating Valuation After Debt Buyback and Steps Toward Greater Financial Flexibility

SS&C Technologies (SSNC): Exploring Valuation After Recent Steady Share Climb

Novartis Receives FDA Approval For Itvisma, The Only Gene Replacement Therapy For Children Two Years And Older, Teens, And Adults With Spinal Muscular Atrophy

FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults